JP2006526644A5 - - Google Patents

Download PDF

Info

Publication number
JP2006526644A5
JP2006526644A5 JP2006515006A JP2006515006A JP2006526644A5 JP 2006526644 A5 JP2006526644 A5 JP 2006526644A5 JP 2006515006 A JP2006515006 A JP 2006515006A JP 2006515006 A JP2006515006 A JP 2006515006A JP 2006526644 A5 JP2006526644 A5 JP 2006526644A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
inhibitor
composition according
aag
enzyme inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
JP2006515006A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006526644A (ja
Filing date
Publication date
Priority claimed from US10/856,696 external-priority patent/US20050020557A1/en
Application filed filed Critical
Publication of JP2006526644A publication Critical patent/JP2006526644A/ja
Publication of JP2006526644A5 publication Critical patent/JP2006526644A5/ja
Abandoned legal-status Critical Current

Links

JP2006515006A 2003-05-30 2004-05-28 Hsp−90阻害剤を酵素インヒビターとのコンビネーションにおいて使用する疾患の治療方法 Abandoned JP2006526644A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US47490603P 2003-05-30 2003-05-30
US10/856,696 US20050020557A1 (en) 2003-05-30 2004-05-27 Method for treating diseases using HSP90-inhibiting agents in combination with enzyme inhibitors
PCT/US2004/016889 WO2005000213A2 (en) 2003-05-30 2004-05-28 Method for treating diseases using hsp90-inhibiting agents in combination with enzyme inhibitors

Publications (2)

Publication Number Publication Date
JP2006526644A JP2006526644A (ja) 2006-11-24
JP2006526644A5 true JP2006526644A5 (cg-RX-API-DMAC7.html) 2007-07-12

Family

ID=34083152

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006515006A Abandoned JP2006526644A (ja) 2003-05-30 2004-05-28 Hsp−90阻害剤を酵素インヒビターとのコンビネーションにおいて使用する疾患の治療方法

Country Status (4)

Country Link
US (1) US20050020557A1 (cg-RX-API-DMAC7.html)
EP (1) EP1628623A4 (cg-RX-API-DMAC7.html)
JP (1) JP2006526644A (cg-RX-API-DMAC7.html)
WO (1) WO2005000213A2 (cg-RX-API-DMAC7.html)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090197852A9 (en) * 2001-08-06 2009-08-06 Johnson Robert G Jr Method of treating breast cancer using 17-AAG or 17-AG or a prodrug of either in combination with a HER2 inhibitor
US6872715B2 (en) * 2001-08-06 2005-03-29 Kosan Biosciences, Inc. Benzoquinone ansamycins
US7154002B1 (en) 2002-10-08 2006-12-26 Takeda San Diego, Inc. Histone deacetylase inhibitors
US7375228B2 (en) * 2003-03-17 2008-05-20 Takeda San Diego, Inc. Histone deacetylase inhibitors
US20050020534A1 (en) * 2003-05-30 2005-01-27 Kosan Biosciences, Inc. Method for treating diseases using HSP90-inhibiting agents in combination with antimetabolites
US20050020556A1 (en) * 2003-05-30 2005-01-27 Kosan Biosciences, Inc. Method for treating diseases using HSP90-inhibiting agents in combination with platinum coordination complexes
US20050026893A1 (en) * 2003-05-30 2005-02-03 Kosan Biosciences, Inc. Method for treating diseases using HSP90-inhibiting agents in combination with immunosuppressants
EP1638541B1 (en) * 2003-06-27 2010-05-19 Astellas Pharma Inc. Therapeutic agent for soft tissue sarcoma
US20050137234A1 (en) * 2003-12-19 2005-06-23 Syrrx, Inc. Histone deacetylase inhibitors
WO2005065681A1 (en) * 2003-12-19 2005-07-21 Takeda San Diego, Inc. N- hydroxy-3-(3-(1h-imidazol-2-yl)-phenyl)-acrylamide derivatives and related compounds as histone deacetylase (hdac) inhibitors for the treatment of cancer
ES2594874T3 (es) * 2004-11-18 2016-12-23 Synta Pharmaceuticals Corp. Compuestos de triazol que modulan la actividad de HSP90
US7642275B2 (en) * 2004-12-16 2010-01-05 Takeda San Diego, Inc. Histone deacetylase inhibitors
DE102005007304A1 (de) 2005-02-17 2006-08-24 Merck Patent Gmbh Triazolderivate
JP2008540574A (ja) * 2005-05-11 2008-11-20 タケダ サン ディエゴ インコーポレイテッド ヒストンデアセチラーゼ阻害剤
CA2615105A1 (en) * 2005-07-14 2007-01-25 Takeda San Diego, Inc. Histone deacetylase inhibitors
US20080200488A1 (en) * 2005-08-11 2008-08-21 Manley Paul W Combinations Comprising a Protein Kinase Inhibitor Being a Pyrimidylaminobenzamide Compound and a Hsp90 Inhibitor Such as 17-Aag
CA2618628C (en) 2005-08-18 2014-11-18 Synta Pharmaceuticals Corp. Triazole compounds that modulate hsp90 activity
CA2627129A1 (en) * 2005-11-04 2007-05-18 Merck & Co., Inc. Methods of using saha and bortezomib for treating cancer
US20090042847A1 (en) * 2005-11-23 2009-02-12 Kosan Biosciences Incorporated 17-allylamino-17-demethoxygeldanamycin polymorphs and formulations
US7648976B2 (en) * 2005-11-23 2010-01-19 Bristol-Myers Squibb Company 17-allylamino-17-demethoxygeldanamycin polymorphs and formulations
EP1976835A2 (en) * 2006-01-13 2008-10-08 Takeda San Diego, Inc. Histone deacetylase inhibitors
US20080027047A1 (en) * 2006-05-25 2008-01-31 Weiwen Ying Compounds that modulate HSP90 activity and methods for identifying same
CA2667348A1 (en) * 2006-11-03 2008-05-15 University Of Maryland, Baltimore Methods of using saha and bortezomib for treating multiple myeloma
DE102007002715A1 (de) 2007-01-18 2008-07-24 Merck Patent Gmbh Triazolderivat
US8266791B2 (en) * 2007-09-19 2012-09-18 The Charles Stark Draper Laboratory, Inc. Method of fabricating microfluidic structures for biomedical applications
US20090234332A1 (en) * 2008-03-17 2009-09-17 The Charles Stark Draper Laboratory, Inc Artificial microvascular device and methods for manufacturing and using the same
US9205086B2 (en) 2010-04-19 2015-12-08 Synta Pharmaceuticals Corp. Cancer therapy using a combination of a Hsp90 inhibitory compounds and a EGFR inhibitor
AU2012332424A1 (en) 2011-11-02 2014-06-05 Synta Pharmaceuticals Corp. Combination therapy of Hsp90 inhibitors with platinum-containing agents
WO2013067162A1 (en) 2011-11-02 2013-05-10 Synta Pharmaceuticals Corp. Cancer therapy using a combination of hsp90 inhibitors with topoisomerase i inhibitors
WO2013074594A1 (en) 2011-11-14 2013-05-23 Synta Pharmaceuticals Corp. Combination therapy of hsp90 inhibitors with braf inhibitors
US9421315B2 (en) 2012-09-05 2016-08-23 The Charles Stark Draper Laboratory, Inc. Compact hydraulic manifold structure for shear sensitive fluids
US9656212B2 (en) 2013-01-08 2017-05-23 The Charles Stark Draper Laboratory, Inc. Compact hydraulic manifold structure for shear sensitive fluids
US9784396B2 (en) 2014-02-17 2017-10-10 The Charles Stark Draper Laboratory, Inc. Microfluidic manifold for shear sensitive fluids
KR20160015076A (ko) 2014-07-30 2016-02-12 삼성전자주식회사 c-Met 저해제의 효능 예측을 위한 바이오마커 Hsp90
KR102259232B1 (ko) 2014-08-25 2021-05-31 삼성전자주식회사 항 c-Met/항 Ang2 이중 특이 항체

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4261989A (en) * 1979-02-19 1981-04-14 Kaken Chemical Co. Ltd. Geldanamycin derivatives and antitumor drug
ATE194767T1 (de) * 1992-03-23 2000-08-15 Univ Georgetown In liposomen verkapseltes taxol und verwendungsverfahren
US5387584A (en) * 1993-04-07 1995-02-07 Pfizer Inc. Bicyclic ansamycins
AU6833994A (en) * 1993-05-17 1994-12-12 Liposome Company, Inc., The Incorporation of taxol into liposomes and gels
US5415869A (en) * 1993-11-12 1995-05-16 The Research Foundation Of State University Of New York Taxol formulation
US5932566A (en) * 1994-06-16 1999-08-03 Pfizer Inc. Ansamycin derivatives as antioncogene and anticancer agents
US5662883A (en) * 1995-01-10 1997-09-02 Nanosystems L.L.C. Microprecipitation of micro-nanoparticulate pharmaceutical agents
US5534270A (en) * 1995-02-09 1996-07-09 Nanosystems Llc Method of preparing stable drug nanoparticles
US5510118A (en) * 1995-02-14 1996-04-23 Nanosystems Llc Process for preparing therapeutic compositions containing nanoparticles
PL189698B1 (pl) * 1996-03-12 2005-09-30 Pg Txl Co Kompozycja farmaceutyczna zawierająca lek przeciwnowotworowy i jej zastosowania
US6682758B1 (en) * 1998-12-22 2004-01-27 The United States Of America As Represented By The Department Of Health And Human Services Water-insoluble drug delivery system
US6245759B1 (en) * 1999-03-11 2001-06-12 Merck & Co., Inc. Tyrosine kinase inhibitors
US6174875B1 (en) * 1999-04-01 2001-01-16 University Of Pittsburgh Benzoquinoid ansamycins for the treatment of cardiac arrest and stroke
WO2001029025A2 (en) * 1999-10-19 2001-04-26 Merck & Co., Inc. Tyrosine kinase inhibitors
US6313138B1 (en) * 2000-02-25 2001-11-06 Merck & Co., Inc. Tyrosine kinase inhibitors
WO2002060430A1 (en) * 2001-02-01 2002-08-08 Cornell Research Foundation, Inc. Use of retinoids plus histone deacetylase inhibitors to inhibit the growth of solid tumors
PT1373215E (pt) * 2001-03-30 2006-12-29 Uni S Of A R By The S D Of H H Derivado de geldanamicina e metodo de tratamento de cancro utilizando o mesmo
US6872715B2 (en) * 2001-08-06 2005-03-29 Kosan Biosciences, Inc. Benzoquinone ansamycins
EP1420747A4 (en) * 2001-08-06 2010-06-02 Kosan Biosciences Inc ANSAMYCIN BENZOQUINONE

Similar Documents

Publication Publication Date Title
WO2008040534A3 (en) Non-mucoadhesive film dosage forms
NO20062504L (no) Sammensetninger og doseringsformer for forbedret absorpsjon
CN109640981A (zh) 神经激肽-1拮抗剂用于治疗多种瘙痒病症的用途
CN1440283A (zh) 有机化合物的联合形式
WO2004073632A3 (en) Rapid absorption selective 5-ht agonist formulations
JP2007523049A5 (cg-RX-API-DMAC7.html)
NO20092033L (no) Nye forbindelser
ATE543489T1 (de) Orale dosierformen mit progesteron und verwendungs- und herstellungsverfahren dafür
CA2505964A1 (en) Pharmaceutical compositions and dosage forms of thalidomide
WO2004037190A3 (en) Modified release compositions of milnacipran
AU2003210300A1 (en) The use of tnf-alpha antagonist as drugs for the treatment of patients with sepsis and without suffering from total organ failure
NO20060185L (no) Anvendelse av isomalt (blanding av 1,6 GPS og 1,1 GPM) som prebiotikum blant annet for fremstilling av et legemiddel for behandling av tarmsykdommer
UA84694C2 (ru) Капсула для лечения дизурии, содержащая гранулиновое индолиновое соединение - блокатор -адренорецепторов
WO2008008474A3 (en) Compositions and methods for the treatment of chronic pain conditions
FI3220916T3 (fi) Menetelmä syövän hoitoon n-((4,6-dimetyli-2-okso-1,2-dihydropyridin-3-yyli)metyyli)-5-(etyyli(tetrahydro-2h-pyran-4-yyli)amino)- 4-metyyli-4'-(morfolinometyyli)-[1,1'-bifenyyli]-3-karboksamidilla
JP5784274B2 (ja) Hdac阻害剤と代謝拮抗剤の組み合わせ
EP1633402A2 (en) Pharmaceutical composition
NO20074933L (no) Farmasoytisk sammensetning som innbefatter et indolylmaleimidderivat
EP2281561A3 (en) Use of LCK inhibitors for treatment of immunologic diseases
TW200624431A (en) Phthalazinone derivatives, their manufacture and use as pharmaceutical agents
BRPI0816798A2 (pt) composto, composição farmacêutica, métodos para inibir a ação do glicogênio sintase cinase-3, e para tratar, prevenir ou melhorar uma doença, uso de um composto, e, artigo de fabricação
Kandula et al. Discovery and preclinical development of a novel prodrug conjugate of mesalamine with eicosapentaenoic acid and caprylic acid for the treatment of inflammatory bowel diseases
JP2009518415A5 (cg-RX-API-DMAC7.html)
WO2004112794A3 (en) New pharmaceutical uses of staurosporine derivatives
RU2006117790A (ru) Применение производного пиразола для получения лекарственного средства, пригодного для профилактики и лечения дислипидемий и заболеваний, связанных с дислипидемиями и/или с ожирением